Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

SRP2151

Sigma-Aldrich

HCV-NS4A/NS3-1b Protease, Histag, strain HC-J4 from hepatitis C virus

recombinant, expressed in E. coli, ≥80% (SDS-PAGE)

Sinônimo(s):

Hepatitis C virus NS3 protease, NS3, NS4ANS3 complex, pfam02907

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Código UNSPSC:
12352204
NACRES:
NA.26

fonte biológica

hepatitis C virus

recombinante

expressed in E. coli

Ensaio

≥80% (SDS-PAGE)

Formulário

frozen liquid

peso molecular

~22.7 kDa

embalagem

pkg of 10 μg

concentração

500 μg/mL

cor

colorless to clear

nº de adesão NCBI

X61596

Condições de expedição

dry ice

temperatura de armazenamento

−70°C

Informações sobre genes

hepatitis C virus ... HCVgp1(951475)

Ações bioquímicas/fisiológicas

Persistent infection with hepatitis C virus (HCV) is a common cause of chronic liver disease, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV is an enveloped, single-stranded RNA virus with a 9.6-kb positive-polarity genome, which encodes a polyprotein precursor of about 3,000 amino acids. The HCV polyprotein is proteolytically processed by cellular and HCV proteases into at least 10 distinct products. NS3 serine protease and helicase as well as NS5B RNA-dependent RNA polymerase are believed to be components of a replication complex responsible for viral RNA replication and have been shown to be essential for the HCV replication in chimpanzees. These HCV enzymes have been the major targets for the development of HCV-specific therapeutics during the past decade. The HCV NS3/4A protease is responsible for cleavage at four sites within the HCV polyprotein to generate the N termini of the NS4A, NS4B, NS5A, and NS5B proteins. It has been shown that the central region (amino acids 21-30) of the 54-residue NS4A protein is essential and sufficient for the enhancement of proteolytic activity of the NS3 serine protease. In recent phase I trials, a 2-3-log reduction of HCV viral load was observed after a 2-day treatment with a serine protease inhibitor, which provided the first proof-of-concept evidence that HCV NS3/4A protease inhibitors could be a new therapeutic option for hepatitis C patients.

forma física

Clear and colorless frozen liquid solution

Nota de preparo

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. While working, please keep sample on ice.

Código de classe de armazenamento

10 - Combustible liquids

Classe de risco de água (WGK)

WGK 1

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

A A Kolykhalov et al.
Journal of virology, 74(4), 2046-2051 (2000-01-22)
Hepatitis C virus (HCV) infection is a widespread major human health concern. Significant obstacles in the study of this virus include the absence of a reliable tissue culture system and a small-animal model. Recently, we constructed full-length HCV cDNA clones
Blight, K. J., et al.
Antiviral Ther., 3, 71-81 (1998)
M J Alter
Hepatology (Baltimore, Md.), 26(3 Suppl 1), 62S-65S (1997-09-26)
In the United States, the annual number of newly acquired acute hepatitis C virus (HCV) infections has declined from an estimated 180,000 in the mid 1980s to an estimated 28,000 in 1995. Approximately 25% to 30% of these infections are

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica